Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BillionToOneBLLN -0.25%15 EV-to-OCF is 89.95 as of Aug. 21, 2026, which is 35% below its 10-year median of 138.25. GuruFocus rates BLLN with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, BillionToOne ranks worse than 97.17% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, BillionToOne's Enterprise Value is $4,079.5 Mil.
BillionToOne's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $45.4 Mil. Therefore, BillionToOne's EV-to-OCF for today is 89.95.
The historical rank and industry rank for BillionToOne's EV-to-OCF or its related term are showing as below:
BLLN'
s EV-to-OCF Range Over the Past 10 Years
Min: 89.79 Med: 138.25 Max: 1065.92
Current: 89.95
During the past 3 years, the highest EV-to-OCF of BillionToOne was 1065.92. The lowest was 89.79. And the median was 138.25.
BLLN's EV-to-OCF is ranked worse than 97.17% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.055
vs BLLN: 89.95
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BillionToOne's PE Ratio (TTM) for today is calculated as:
BillionToOne's share price for today is $95.05.
BillionToOne's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.634.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BillionToOne EV-to-OCF Related Terms
BillionToOne EV-to-OCF Historical Data
* Premium members only.
The historical data trend for BillionToOne's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, BillionToOne's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BillionToOne EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where BillionToOne's EV-to-OCF falls into.
BillionToOne's current Enterprise Value is $4,079.5 Mil.
BillionToOne's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $45.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BillionToOne (BLLN) has a EV-to-OCF of 89.95 as of Aug. 21, 2026. This is 35% below median its historical median of 138.25. Over the past decade, BillionToOne's EV-to-OCF has ranged from 89.79 to 1,065.92. According to the industry distribution chart, BillionToOne ranks #206 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 97.2%.
Is BillionToOne's EV-to-OCF too high?
BillionToOne's current EV-to-OCF of 89.95 is 35% below median its 10-year median of 138.25. Over the past 10 years, this metric has ranged from a low of 89.79 to a high of 1,065.92. The Medical Diagnostics & Research industry median EV-to-OCF is 6.06. BillionToOne's value of 89.95 is 1385.5% above this industry median. Based on the distribution chart, BillionToOne ranks #206 out of 212 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, BillionToOne has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's EV-to-OCF compare to TWST and SHC?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #206 out of 212 companies for EV-to-OCF. This places BillionToOne in the lower half of its industry. The industry median EV-to-OCF is 6.06. BillionToOne's value of 89.95 is 1385.5% above this benchmark. Historically, BillionToOne's own EV-to-OCF has ranged from 89.79 to 1,065.92 over the past decade. While the company's 10-year median is 138.25 vs. the industry median of 6.06, BillionToOne has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.06, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BillionToOne's current EV-to-OCF of 89.95 is 1385.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BillionToOne's current EV-to-OCF is 89.95, which is 35% below median its own 10-year median of 138.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current EV-to-OCF of 89.95. The current EV-to-OCF is 89.95, which is 35% below median its 10-year median of 138.25 and 1385.5% above the Medical Diagnostics & Research industry median of 6.06. BillionToOne's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For BillionToOne (BLLN), the current EV-to-OCF is 89.95 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
15GF Score
Get the complete analysis for BLLN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLN has been successfully added to your 
